SCHEMBL25065522

SCHEMBL25065522

CCc1ncn(C)c(=O)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 6/20 0.36
▸ PDE4A P27815 5/20 0.36
▸ PDE4B Q07343 5/20 0.36
▸ PDE4C Q08493 5/20 0.36
▸ PDE4D Q08499 5/20 0.36
▸ ADORA2B P29275 3/20 0.36
▸ BLM P54132 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ PMP22 Q01453 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ APOBEC3A P31941 1/20 0.33
▸ APOBEC3G Q9HC16 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ GDA Q9Y2T3 2/20 0.32
▸ PIK3CD O00329 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ ACHE P22303 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14580329 0.71 — —
SCHEMBL4381073 0.70 — —
SCHEMBL16544559 0.67 CDK1 (0.34) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL24248823 0.67 GDA (0.32) ADORA2AADORA2BBLMCYP3A4PMP22
SCHEMBL2629330 0.64 — —
SCHEMBL13113070 0.62 KDM5B (0.42) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL12375379 0.62 CDK1 (0.41) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL16480138 0.61 PDE4A (0.39) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL251821 0.61 — —
SCHEMBL19663162 0.61 DHFR (0.33) CYP1A2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 ADORA2A 2001/4885PDE4A 731/4885PDE4B 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback